You are here: Industry Insights > ASCVD

News List

FDA Approves Leqvio (inclisiran), First-in-Class siRNA to Reduce Low-Density Lipoprotein Cholesterol (LDL-C) Drugs
December 27, 2021
Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol...
FDA approves add-on therapy to lower cholesterol among certain high-risk adults FDA
December 23, 2021
FDA has approved Leqvio (inclisiran) injection as a treatment to be used along with diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia (HeFH)...
Financial Toxicity More Prevalent for ASCVD Than Cancer Patients drugs
June 16, 2021
Financial toxicity (FT) is more prevalent among individuals with atherosclerotic cardiovascular disease (ASCVD) than individuals with cancer, according to a study published in the June 1 issue of JACC: CardioOncology.
Novo snaps up cardio-renal group Corvidia pharmatimes
June 16, 2020
Novo Nordisk has signed a deal to acquire Corvidia Therapeutics, a privately held, clinical stage company with a focus on the research and development of transformative therapies for cardio-renal diseases.
FDA approves Esperion’s non-statin LDL-C lowering drug pharmaceutical-technology
March 03, 2020
Esperion has announced the US Food and Drug Administration (FDA) has approved Nexlizet (bempedoic acid and ezetimibe).
Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk drugs
December 26, 2019
Elevated concentrations of non-high-density lipoprotein (non-HDL) cholesterol are associated with an increased long-term risk for atherosclerotic cardiovascular disease ...
BP, Waist Circumference, Lipids Should Be Measured Regularly drugs
August 06, 2019
Blood pressure, waist circumference, fasting lipid profile, and blood glucose should be measured regularly to identify atherosclerotic cardiovascular disease (ASCVD)...
Nonfasting Lipid Levels Adequate for Assessing Cardiovascular Risk drugs
June 03, 2019
Nonfasting Lipid Levels Adequate for Assessing Cardiovascular Risk.
Women With CVD Have Worse Self-Reported Outcomes drugs
January 09, 2019
Compared with men, women with atherosclerotic cardiovascular disease (ASCVD) are more likely to report poorer patient experience, lower health-related quality of life......